Updates in the Treatment of Frontline and R/R cHL: Clinical Applicat…

Stephen M. Ansell

ASH & ISHL 2024 Summary: Key Clinical Questions & Highlights in cHL

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

2024 Updates in the Management of DLBCL, FL, and HL

UNC Lineberger Comprehensive Cancer Center

A. Beaven

2022 Sedona ASCO Updates on the Frontline Hodgkin Lymphoma: 1L Chemo…

Total Health

B. Haverkos

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon

SOHO 2021 Next Questions in Hodgkin Lymphoma

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

C. Moskowitz

Are Checkpoint Inhibitors the SOC in Frontline Hodgkin Lymphoma?

UChicago Medicine

B. Hu

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

The Potential Role of ctDNA in Hodgkin Lymphoma Management

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

I. Panovska-Stavridis

SOHO Turkey 2023: How I Treat Hodgkin Lymphoma

SOHO Turkey 2023

T. Toptas

ASH 2023 Insights: "BrECADD Combined With PET2-Guided Treatment for …

ecancer

P. Borchmann

Brentuximab Vedotin + AVD vs. ABVD in Advanced cHL: What Is the 5-Ye…

David Straus

UChicago Medicine Best of ASCO® 2024: HL, DLBCL, MCL

UChicago Medicine Annual Practice Updates in Hematology and Oncology

A. Rojek

What Is Nodular Lymphocyte Predominant Hodgkin Lymphoma and How Do Y…

PrecisCa

J. Abramson

Classical Hodgkin Lymphoma: Subtypes and Differential Diagnosis

Judith Ann Ferry

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

William Schaffner

Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Clinical an…

Judith Ann Ferry

ASCO® 2024 Summary: "Treatment Considerations for Challenging Popula…

2024 ASCO® Annual Meeting Insights Hub

C. Burton

Updates on Allogeneic Stem Cell Transplant

Yale Cancer Center

L. Bachegowda